Elanco US Enters into Agreement to Acquire Boehringer Ingelheim Vetmedica’s U.S. Feline, Canine and Rabies Vaccine Portfolio for $885 Million
NEW YORK – Paul Hastings LLP, a leading global law firm, represented Elanco US Inc, a subsidiary of Eli Lilly and Company, in an agreement to acquire Boehringer Ingelheim Vetmedica’s U.S. feline, canine and rabies vaccines portfolio - as well as a fully integrated manufacturing and R&D site - for $885 million, including the estimated cost of acquired inventory. The deal will diversify Elanco's U.S. companion animal portfolio by complementing its offerings for dogs and cats.
Joining Elanco’s U.S. portfolio - which includes paraciticides, pain and dermatology medicines– will be routinely administered vaccines for bordetella, Lyme disease, rabies, and parvovirus, among others. Also included in the agreement are several pipeline assets.
The acquisition is anticipated to close by early 2017, subject to approval by the Federal Trade Commission and also subject to antitrust approval and closing of Boehringer Ingelheim's asset swap transaction with Sanofi.
The Paul Hastings team was led by Mergers and Acquisitions partner
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.